Viewing nowCombinationPromet XR Controlled-Release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.

MFDS item code 202201969 · Approved 2022.05.11 · Insurance code 654005930
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used together with dietary and exercise therapy to help control blood sugar in patients with type 2 diabetes. It aids in effectively managing blood sugar levels by combining sitagliptin and metformin, thus playing a crucial role in maintaining stable blood sugar levels.
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient’s existing metformin dose. Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their existing doses of sitagliptin and metformin. Patients receiving immediate-release metformin at an existing dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking the patient’s blood glucose level and existing dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains both sitagliptin and metformin to assist with blood sugar control in patients with type 2 diabetes. First, sitagliptin can rarely cause severe allergic reactions; if symptoms such as skin rash, difficulty breathing, or swelling of the face or throat occur, discontinue use immediately and consult a doctor. Additionally, sitagliptin carries a risk of acute pancreatitis, so if symptoms such as abdominal pain, nausea, vomiting, or loss of appetite occur, monitor closely and inform a physician. The metformin component can rarely induce a serious condition known as lactic acidosis, which is dangerous due to excessive lactic acid buildup in the body. If symptoms such as fatigue, muscle pain, difficulty breathing, or abdominal pain occur, immediate medical attention is required. This medication should not be used in patients with moderate to severe renal impairment, acute heart failure or myocardial infarction, or patients in acute infection or dehydration states; it should also be temporarily discontinued before and after examinations using contrast agents. Administration is not recommended for pregnant women, women who could become pregnant, nursing mothers, or children under 18 years of age. When taking this medication, regular kidney function, blood tests, and Vitamin B12 levels should be monitored, and alcohol consumption should be avoided. This medication can cause hypoglycemia; therefore, caution is needed when skipping meals or engaging in intense exercise. The risk of hypoglycemia may increase when taken with other blood glucose-lowering agents, necessitating dosage adjustments after consulting a doctor. If surgery is planned, discontinue use 48 hours prior to the surgery, and resume only after confirming normal kidney function post-surgery. In case of severe joint pain or the appearance of blisters on the skin during treatment, inform a doctor immediately and seek treatment. Finally, this medication can interact with several other drugs, so if you are taking other medications, it's essential to inform your doctor or pharmacist, and consult medical personnel immediately if any discomfort arises.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, blistering bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, hypoglycemic episodes, rash, urticaria, cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to prevent air and moisture from entering, ideally at a temperature between 1 and 30 degrees Celsius. This storage method helps maintain the drug's effectiveness for a longer period.
Bright green, convex on both sides, oval-shaped controlled-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.